BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wagner E, Löhrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019;33:423-35. [PMID: 30696332 DOI: 10.1177/0269881118822171] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Grover S, Sarkar S, Sahoo S. Augmentation strategies for clozapine resistance: a systematic review and meta-analysis. Acta Neuropsychiatr 2022;:1-11. [PMID: 36380513 DOI: 10.1017/neu.2022.30] [Reference Citation Analysis]
2 de Bartolomeis A, Ciccarelli M, Vellucci L, Fornaro M, Iasevoli F, Barone A. Update on novel antipsychotics and pharmacological strategies for treatment resistant schizophrenia. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2145884] [Reference Citation Analysis]
3 Zheng S, Chan SKW, Lee J. Managing treatment resistance in schizophrenia: A joint study in Hong Kong and Singapore. Front Psychiatry 2022;13:1005373. [DOI: 10.3389/fpsyt.2022.1005373] [Reference Citation Analysis]
4 Neill E, Rossell SL, Yolland C, Meyer D, Galletly C, Harris A, Siskind D, Berk M, Bozaoglu K, Dark F, Dean OM, Francis PS, Liu D, Phillipou A, Sarris J, Castle DJ. N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms. Schizophr Bull 2022;48:1263-72. [PMID: 35857752 DOI: 10.1093/schbul/sbac065] [Reference Citation Analysis]
5 Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes OD. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs 2022. [PMID: 35759211 DOI: 10.1007/s40263-022-00932-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Miura G, Tanaka K, Kemuriyama T, Misawa F, Uchida H, Mimura M, Takeuchi H. Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review. Pharmacopsychiatry 2022. [PMID: 35512817 DOI: 10.1055/a-1811-7318] [Reference Citation Analysis]
7 Oloyede E, Clark I, Mace S, Whiskey E, Taylor D. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Therapeutic Advances in Psychopharmacology 2022;12:204512532110666. [DOI: 10.1177/20451253211066642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Dubatova IV, Antsyborov LA, Kheigetian AF, Antsyborov AV. “Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists? ISci 2021. [DOI: 10.21661/r-555399] [Reference Citation Analysis]
9 Corrales A, Gargoloff P, Viiapriño M, Rebok F. P.0902 Pattern of use of clozapine in Argentina. European Neuropsychopharmacology 2021;53:S662-S663. [DOI: 10.1016/j.euroneuro.2021.10.758] [Reference Citation Analysis]
10 Siskind D, Sharma M, Pawar M, Pearson E, Wagner E, Warren N, Kisely S. Clozapine levels as a predictor for therapeutic response: A systematic review and meta-analysis. Acta Psychiatr Scand 2021;144:422-32. [PMID: 34374073 DOI: 10.1111/acps.13361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
11 Wagner E, Siafis S, Fernando P, Falkai P, Honer WG, Röh A, Siskind D, Leucht S, Hasan A. Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. Transl Psychiatry 2021;11:487. [PMID: 34552059 DOI: 10.1038/s41398-021-01613-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
12 Fernandez-Egea E, Chen S, Jenkins C, Turrion C, Mitchell SP, Dodwell DJF, Mann LM, Deakin JB, Syed ZH, Hafizi S, Zimbron J, Praseedom AS, Cardinal RN. The Effect of Clozapine on Self-reported Duration of Sleep and Its Interaction With 23 Other Medications: A 5-Year Naturalistic Study. J Clin Psychopharmacol 2021;41:534-9. [PMID: 34519455 DOI: 10.1097/JCP.0000000000001432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability. The Clinical Use of Antipsychotic Plasma Levels 2021. [DOI: 10.1017/9781009002103.008] [Reference Citation Analysis]
14 Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatr 2021; 11(8): 429-448 [PMID: 34513606 DOI: 10.5498/wjp.v11.i8.429] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
15 Tsukiji M, Sasaki T, Nakata Y, Ota K, Aoki T, Hara K, Mamada T, Nakane J, Kogure M, Seki R, Idemoto K, Hashimoto T, Koishikawa H, Moriyama T, Suzuki T, Kanahara N, Ishii I, Iyo M, Niitsu T. Risk factors for early-phase clozapine discontinuation: A nested case-control study. Asian J Psychiatr 2021;62:102745. [PMID: 34216977 DOI: 10.1016/j.ajp.2021.102745] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Soares DS, Carvalho DR, Ribeiro MDT, Diniz EJB, Rêgo AF Neto. Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil. Trends Psychiatry Psychother 2021. [PMID: 34139114 DOI: 10.47626/2237-6089-2020-0151] [Reference Citation Analysis]
17 Kang SH. Change of Prescribing Pattern after Clozapine Discontinuation: A Retrospective Chart Review. Korean J Schizophr Res 2021;24:36-43. [DOI: 10.16946/kjsr.2021.24.1.36] [Reference Citation Analysis]
18 Luykx JJ, Stam N, Tanskanen A, Tiihonen J, Taipale H. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. Br J Psychiatry. 2020;217:498-505. [PMID: 31910911 DOI: 10.1192/bjp.2019.267] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
19 Lin CH, Chen YM, Lane HY. Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Curr Drug Targets 2020;21:610-5. [PMID: 31660823 DOI: 10.2174/1389450120666191011163539] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
20 Campana M, Falkai P, Siskind D, Hasan A, Wagner E. Characteristics and definitions of ultra-treatment-resistant schizophrenia - A systematic review and meta-analysis. Schizophr Res 2021;228:218-26. [PMID: 33454644 DOI: 10.1016/j.schres.2020.12.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
21 Ntephe CU, Demjaha A. Dopamine and Response to Antipsychotic Medication. PET and SPECT in Psychiatry 2021. [DOI: 10.1007/978-3-030-57231-0_14] [Reference Citation Analysis]
22 Yi W, She S, Zhang J, Wu H, Zheng Y, Ning Y. <p>Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital</p>. NDT 2020;Volume 16:2827-2836. [DOI: 10.2147/ndt.s261503] [Reference Citation Analysis]
23 Todorovic A, Lal S, Dark F, De Monte V, Kisely S, Siskind D. CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis. Journal of Mental Health. [DOI: 10.1080/09638237.2020.1836558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Dellazizzo L, Potvin S, Phraxayavong K, Dumais A. Exploring the Benefits of Virtual Reality-Assisted Therapy Following Cognitive-Behavioral Therapy for Auditory Hallucinations in Patients with Treatment-Resistant Schizophrenia: A Proof of Concept. J Clin Med 2020;9:E3169. [PMID: 33007909 DOI: 10.3390/jcm9103169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
25 Chauhan P, Garg S, Tikka SK, Khattri S. Efficacy of Intensive Cerebellar Intermittent Theta Burst Stimulation (iCiTBS) in Treatment-Resistant Schizophrenia: a Randomized Placebo-Controlled Study. Cerebellum 2021;20:116-23. [PMID: 32964381 DOI: 10.1007/s12311-020-01193-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
26 Yang L, Liu F, Yuan Q, Zhu J, Wang W, Li X, He J. Fluoxetine attenuates prepulse inhibition deficit induced by neonatal administration of MK-801 in mice. Neuroreport 2020;31:1128-33. [PMID: 32956214 DOI: 10.1097/WNR.0000000000001524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. Br Med Bull 2020;135:73-89. [PMID: 32885238 DOI: 10.1093/bmb/ldaa024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
28 Barnes TRE, MacCabe JH, Kane JM, Delgado O, Paton C. The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. Ther Adv Psychopharmacol 2020;10:2045125320937908. [PMID: 32821377 DOI: 10.1177/2045125320937908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wagner E, Oviedo-Salcedo T, Pelzer N, Strube W, Maurus I, Gutwinski S, Schreiter S, Kleymann P, Morgenroth CL, Okhuijsen-Pfeifer C, Luykx JJ, Falkai P, Schneider-Axmann T, Hasan A. Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine. Pharmacopsychiatry 2020;53:273-83. [PMID: 32757178 DOI: 10.1055/a-1208-0045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
30 Bioque M, Parellada E, García-Rizo C, Amoretti S, Fortea A, Oriolo G, Palau P, Boix-Quintana E, Safont G, Bernardo M. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Eur Psychiatry 2020;63:e71. [PMID: 32669145 DOI: 10.1192/j.eurpsy.2020.72] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
31 Stam N, Taipale H, Tanskanen A, Isphording L, Okhuijsen-Pfeifer C, Schuiling-Veninga CCM, Bos JHJ, Bijker BJ, Tiihonen J, Luykx JJ. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. Clin Transl Sci 2020;13:1170-7. [PMID: 32441836 DOI: 10.1111/cts.12801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Lee J, Falkai P, Schneider-Axmann T, Hasan A;  TRRIP Working Group. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bull. 2020;46:1459-1470. [PMID: 32421188 DOI: 10.1093/schbul/sbaa060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
33 Wagner E, Honer WG, Sommer IE, Koops S, Blumberger DM, Daskalakis ZJ, Dlabac-De Lange JJ, Bais L, Knegtering H, Aleman A, Novak T, Klirova M, Slotema C, Brunelin J, Poulet E, Kujovic M, Cordes J, Wobrock T, Siskind D, Falkai P, Schneider-Axmann T, Hasan A. Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. World J Biol Psychiatry. 2021;22:14-26. [PMID: 32081071 DOI: 10.1080/15622975.2020.1733080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Freudenreich O. Polypharmacy. Psychotic Disorders 2020. [DOI: 10.1007/978-3-030-29450-2_21] [Reference Citation Analysis]
35 Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opin Drug Saf 2020;19:43-57. [PMID: 31770500 DOI: 10.1080/14740338.2020.1698545] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
36 Meyer JM. Commentary: More research needed on predictive biomarkers related to clozapine treatment. Biomarkers in Neuropsychiatry 2019;1:100003. [DOI: 10.1016/j.bionps.2019.100003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Shad MU, Felzien E, Roy K, Sethi S. How to identify and manage non-response to clozapine? Asian J Psychiatr 2019;45:50-2. [PMID: 31494348 DOI: 10.1016/j.ajp.2019.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Freitas R, dos Santos B, Altamura C, Bernasconi C, Corral R, Evans J, Malla A, Krebs M, Nordstroem A, Zink M, Haro JM, Elkis H. Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study. Psychiatry Research 2019;276:210-7. [DOI: 10.1016/j.psychres.2019.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
39 Yun J, Lee JS, Kang SH, Nam B, Lee SJ, Lee S, Choi J, Kim C, Chung Y. Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia. Korean J Schizophr Res 2019;22:21. [DOI: 10.16946/kjsr.2019.22.2.21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]